Amprius Technologies walks into its Q1 2026 print with a striking tension at its core: the stock has rallied 34% over the past month, yet short sellers have been rebuilding positions at a brisk pace throughout April — and a cluster of director-level insiders spent that same rally selling heavily.
The short-side of the story is genuinely material here. Short interest has climbed to 17.1% of the free float — up 28% over the past month — with the sharpest leg of that build coming in the final week of April, when shorts added roughly 535,000 shares in a single session on April 23. That jump brought the position back to levels not seen since the stock began its spring run. The ORTEX short score now reads 61.7, its highest point in the available history and a level that typically reflects above-average bearish conviction. Availability in the lending market has tightened meaningfully: with utilization near 31% and well below the 52-week high of 58.8%, there is still room to add, but the directional trend points toward a tighter borrow pool ahead. Cost to borrow, at 0.48%, remains modest — a signal that shorts are not yet being squeezed, just quietly accumulating.
Options traders are also leaning cautious. The put/call ratio has climbed to 0.61 — the highest reading of the past year and roughly 1.6 standard deviations above its 20-day average of 0.51. That is not a panic reading, but it is a steady drift toward downside protection that has been building for most of April, coinciding exactly with the short-interest rebuild. When both the futures and options positioning move in the same direction across several weeks, the setup is worth noting.
The insider picture adds a further complicating layer. Director Kang Sun sold more than 1.5 million shares on April 1 — two separate transactions totalling roughly $23.9 million — following an additional $4.1 million in sales in late March. Director Wen Hsuan Hsieh made additional sales of approximately $7.6 million in mid-March. The 90-day net sell figure across all insiders comes to roughly $65.7 million in value across 4.6 million net shares. These were executed as the stock traded in the $15–$19 range, well below the current price of $21.40, which means insiders were not selling into weakness — they were distributing into strength.
The analyst community has been uniformly constructive, though the most recent formal actions are now nearly two months old. B. Riley raised its target to $22 following a strong prior earnings print, while Craig-Hallum and Cantor Fitzgerald both lifted targets to $21 and $20 respectively after the same catalyst. The mean target of $19.75 now sits just below the current price, which is a notable shift — the stock has effectively run through consensus. The earnings data reinforces why analysts revised higher: the March print saw a +30% single-day move and a +46% five-day reaction. The one before that delivered a +28% day-one gain. Positive revenue surprises have been the norm, which makes tonight's actual Q1 print — revenue of $28.5 million beating the $25.7 million estimate, against an EPS miss of $(0.04) vs $(0.02) expected — a mixed but largely in-line result. Full-year revenue guidance was raised above $130 million. The EV/EBITDA multiple, at 257x, reflects that the market is pricing in long-run execution, not near-term profits.
Peer PLUG gained 9.6% on the week and TE added 9.0%, suggesting the broader clean-energy complex had tailwinds behind it. That context matters: some of AMPX's gains may reflect sector momentum rather than idiosyncratic strength. Whether the Q1 print — revenue beat, EPS miss, guidance raised — is enough to sustain momentum against a 17% short base that has been building for four weeks is the question the next few sessions will answer.
See the live data behind this article on ORTEX.
Open AMPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
